Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study

Agid, 2003, Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected, Arch. Gen. Psychiatry, 60, 1228, 10.1001/archpsyc.60.12.1228 Agid, 2006, The “delayed onset” of antipsychotic action—an idea whose time has come and gone, J. Psychiatry Neurosci., 31, 93 Bhana, 2001, Olanzapine: an updated review of its use in the management of schizophrenia, Drugs, 61, 111, 10.2165/00003495-200161010-00011 Cleton, 2006, No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects, Clin. Pharmacol. Ther., 79, 22, 10.1016/j.clpt.2005.12.079 Correll, 2003, Early prediction of antipsychotic response in schizophrenia, Am. J. Psychiatry, 160, 2063, 10.1176/appi.ajp.160.11.2063 Emsley, 2006, Time course for antipsychotic treatment response in first-episode schizophrenia, Am. J. Psychiatry, 163, 743, 10.1176/ajp.2006.163.4.743 Ereshefsky, 2003, Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics, J. Clin. Psychiatry, 64, 18 Gagnon, 2006, Reliability, validity and sensitivity to change of the Personal and Social Performance Scale in patients with stable schizophrenia, Int. J. Neuropsychopharmacol., 9, S288 Guy, 1976, 76 Helgason, 1990, Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?, Acta Psychiatr. Scand., 81, 231, 10.1111/j.1600-0447.1990.tb06486.x Jones, 2006, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1), Arch. Gen. Psychiatry, 63, 1079, 10.1001/archpsyc.63.10.1079 Kane, 2007, Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial, Biol. Psychiatry, 90, 147 Karlsson, 2005, Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects, Eur. Neuropsychopharmacol., 15, S385 Kay, 1986 Kramer, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 27, 6, 10.1097/JCP.0b013e31802dda4a Lambert, 2004, Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS, Drugs, 18, 5 Lehman, 1995, Vocational rehabilitation in schizophrenia, Schizophr. Bull., 21, 645, 10.1093/schbul/21.4.645 Leucht, 2005, Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended, Biol. Psychiatry, 57, 1543, 10.1016/j.biopsych.2005.02.023 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med., 353, 1209, 10.1056/NEJMoa051688 Marder, 1997, The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials, J. Clin. Psychiatry, 58, 538, 10.4088/JCP.v58n1205 Marder, S., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., Lowy, A., in press. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo controlled study. Biol. Psychiatry. May, 1980, Predicting outcome of antipstychotic drug treatment from early response, Am. J. Psychiatry, 137, 1088, 10.1176/ajp.137.9.1088 Morosini, 2000, Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning, Acta Psychiatr. Scand., 101, 323, 10.1111/j.1600-0447.2000.tb10933.x Nasrallah, 2005, Defining and measuring clinical effectiveness in the treatment of schizophrenia, Psychiatr. Serv., 56, 273, 10.1176/appi.ps.56.3.273 Patrick, 2006, Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophrenia, Int. J. Neuropsychopharmacol., 9, S287 Peuskens, 1995, Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol, Br. J. Psychiatry, 166, 712, 10.1192/bjp.166.6.712 Rossenu, 2007, Comparison of pharmacodynamic parameters resulting from administration of paliperidone extended-release tablet formulation and an immediate-release formulation of risperidone in subjects with schizophrenia, Clin. Pharmacol. Ther., 81, S62 Spina, 2002, Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs, Epilepsia, 43, 37, 10.1046/j.1528-1157.2002.043s2037.x Stroup, 2006, Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic, Am. J. Psychiatry, 163, 611, 10.1176/ajp.2006.163.4.611 Vermeir, 2005, Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects, Eur. Neuropsychopharmacol., 15, S648 Wyatt, 1991, Neuroleptics and the natural course of schizophrenia, Schizophr. Bull., 17, 325, 10.1093/schbul/17.2.325